ea0029p820 | Endocrine tumours and neoplasia | ICEECE2012
Bianchi A.
, Iacovazzo D.
, Lugli F.
, Fusco A.
, Chiloiro S.
, Mormando M.
, Tartaglione L.
, Grande G.
, Larghi A.
, Schinzari G.
, Doglietto G.
, Margaritora S.
, Perotti G.
, Rindi G.
, Pontecorvi A.
, De Marinis L.
Introduction: Peptide receptor radionuclide therapy (PRRT) is a treatment choice for inoperable or metastasized neuroendocrine tumours and this therapy seems more effective in the biochemical and volume control of disease than somatostatin analogues (SSA).Aims: To demonstrate the efficacy of medical therapy with SSA and PRRT in patients with well and moderately differentiated neuroendocrine tumours.Materials and methods: We evaluat...